Goodwin Procter advised Synaffix on the deal.Synaffix announced a licensing agreement with Amgen to develop next generation of antibody-drug conjugates (ADCs) using Synaffix technology. Under the terms…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
